Ascelia Pharma to meet FDA on Orviglance NDA after complete response letter
Reuters2026/08/17 09:55- Ascelia Pharma scheduled a Type A FDA meeting for Sept. 9, 2026 on the Orviglance New Drug Application.
- Session will address the FDA’s Complete Response Letter issued July 2, 2026, covering clinical, quality, and regulatory topics.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Eli Lilly (LLY.US) launches new Class 1 drug Phase III clinical trial in China
According to the Insight database, Brenipatide is the world's first GLP-1 product to initiate Phase III clinical trials for depression.
Record-breaking! Ferrari (RACE.US) sells its first electric car Luce for $40 million, scarcity premium proven in the market again
The first electric car manufactured by Ferrari (RACE.US) was sold for $40 million at an auction held by Sotheby's, setting a new record for the highest price ever paid for a new car at auction.
UHS completes acquisition of Talkspace
Zumtobel names Heiner Lang CEO, replacing Alfred Felder from Oct. 1
Crypto prices
More
